Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 11/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 9/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372846 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372847 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372879 | 0.86 | CHRNA7 (0.75) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372880 | 0.86 | CHRNA7 (0.75) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372977 | 0.85 | CHRNA7 (0.73) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372976 | 0.85 | CHRNA7 (0.73) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373522 | 0.84 | CHRNA7 (0.73) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373182 | 0.84 | CHRNA7 (0.84) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL3937126 | 0.84 | CHRNA7 (0.84) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373181 | 0.84 | CHRNA7 (0.84) | CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124619-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110071188-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071188-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885CHRNB2 19/4885CHRNA4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.